AstraZeneca(US:AZN) 智通财经网·2025-09-29 08:02Group 1 - AstraZeneca plans to list its stock on the New York Stock Exchange to attract more investors while retaining its trading operations in London and its UK headquarters [1] - The new US listing will replace the existing American Depository Receipts (ADRs) [1] - CEO Pascal Soriot has expressed dissatisfaction with the UK regulatory system, fearing that the UK is falling behind the US and China in competitiveness [1] Group 2 - AstraZeneca has faced increasing disappointment from pharmaceutical companies regarding the UK government's efforts to promote the domestic life sciences industry, particularly in areas such as clinical trial numbers and new drug reimbursement policies [1] - Soriot specifically criticized the UK's refusal to promote AstraZeneca's breast cancer drug Enhertu to a broader patient population, highlighting a breakdown in price negotiations [1] - Handelsbanken downgraded AstraZeneca's rating from "Buy" to "Hold," citing concerns that the company's goal of achieving $80 billion in total revenue by 2030 is overly optimistic [2] Group 3 - AstraZeneca has suspended a £200 million (approximately $272.12 million) investment plan at its Cambridge research center, marking a significant reduction in its domestic operations [2] - This decision represents a setback for the UK government as AstraZeneca is the largest publicly listed company in the country [2]